Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-ESBL IgY for eradication of ESBL-producing Enterobacteriaceae carriage
2009-011446-26Phase 2Completed
- Sponsor
- Uppsala University
- Start
- May 2011
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Intestinal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae, intestinal carriage of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli intestinal carriage comparing Anti-ESBL IgY with Placebo (2 arms). Primary endpoint: Eradication of faecal ESBL carriage at Day 21. Started May 2011; status: completed.
02
Drugs
Anti-ESBL IgY
03
Conditions
Intestinal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceaeintestinal carriage of extended-spectrum beta-lactamase-producing Klebsiella pneumoniaeEscherichia coli intestinal carriage
Beyond the preview
Go deeper on 2009-011446-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011446-26.